U.S. Stock News

Earlier this month, Camden Property Trust filed an $802.865 million shelf registration to offer 7,250,000 common shares of beneficial interest for an ESOP-related program. This sizable ESOP-linked shelf suggests Camden is preparing to use equity more actively in employee ownership and compensation, with potential implications for its capital structure. We’ll now explore how this large ESOP-related equity shelf may affect Camden’s existing investment narrative built around Sun Belt...

Recent coverage highlighted Healthcare Services Group’s strong operational efficiency, including solid receivables turnover, asset utilization, inventory management, and operating margins across its housekeeping, laundry, maintenance, and food service operations for healthcare facilities. The company’s very large average four-quarter earnings surprise of 57.3% has drawn attention to how its execution may be supporting profitability versus expectations. We’ll now examine how Healthcare...

Fed officials are once again talking tough on inflation, and that puts transaction driven banks and broker-dealers under a fresh spotlight. When rate expectations swing, cash sweep balances, trading activity, and client behavior can all shift in ways that matter for your portfolio. This article walks through three U.S. stocks exposed to this latest Fed debate, explaining how the recent news could influence investor sentiment, whether positively or negatively. The stocks covered in the article...

In August 2026, GeneDx launched a nationwide online pathway that lets families of children with global developmental delay, intellectual disability, or epilepsy initiate clinician-guided exome testing directly from GeneDx.com, helping bypass long waits for in-person genetics appointments. This digital access model targets a large pool of underserved pediatric patients and aligns closely with updated American Academy of Pediatrics guidance that supports exome sequencing as a first-tier test,...

Candel Therapeutics, Inc. reported second-quarter 2026 results, with net loss widening to US$38.91 million and basic and diluted loss per share from continuing operations at US$0.52, while first-half 2026 net loss reached US$47.77 million compared with net income in the prior-year period. The sharp shift from profitability to loss over six months highlights a significant change in Candel Therapeutics’ operating profile that investors will scrutinize closely. We will now examine how this...

In August 2026, Charter Communications’ subsidiaries completed a large debt refinancing, exchanging multiple long-dated bonds for new 7.087% 2038 and 7.337% 2041 senior secured notes, while Spectrum and Optimum agreed to restore and expand carriage of NY1, News 12 and Spectrum News across key U.S. markets. By reshaping its debt profile and broadening distribution of its local news channels alongside expanded ad sales cooperation, Charter is aiming to improve financial flexibility and unlock...

Scholar Rock Holding (SRRK) is back in focus after its latest quarterly update, which combined ongoing net losses with detailed progress on apitegromab’s U.S. and EU regulatory reviews as well as expansion into new neuromuscular disease studies. See our latest analysis for Scholar Rock Holding. Scholar Rock Holding’s latest regulatory milestones and ongoing net losses have come alongside firm positive momentum, with the share price returning 18.42% over 90 days and 32.03% year to date, and a...

The recent shareholder proposal targeting Darden Restaurants (DRI) board election policies has pushed governance to the forefront ahead of the company’s September 23 annual meeting and drawn fresh attention to the stock’s recent performance metrics. See our latest analysis for Darden Restaurants. Against this governance backdrop, Darden Restaurants’ recent share price performance has stayed in focus, with a 13.9% 1 month share price return and an 18.5% year to date share price return,...

In recent months, Rogers Corporation has outlined ongoing portfolio optimization efforts, including exploring the sale of underperforming legacy businesses and emphasizing organic growth over acquisitions to enhance earnings quality and financial flexibility. This shift in focus has drawn fresh investor attention because it highlights a cleaner, more focused business mix that could reshape how the company allocates capital and manages risk. We’ll now examine how Rogers’ renewed emphasis on...

Ciena (CIEN) is back in focus after e& UAE selected the company’s optical and software platforms for a Dense Wavelength Division Multiplexing network, a contract that touches both Ciena’s technology mix and client concentration story. See our latest analysis for Ciena. The e& UAE contract follows a mixed period for Ciena’s stock, with a 1 day share price return of a 1.50% decline and a 7 day share price return of a 7.54% decline. At the same time, the year to date share price return of 62.35%...

Lithia Motors (LAD) is back in the spotlight after Lithia & Driveway secured a place on the Fortune Global 500 for the second year, moving to No. 426 and reinforcing its expanding automotive retail footprint. See our latest analysis for Lithia Motors. The Fortune Global 500 recognition arrives at a time when Lithia Motors’ share price has gained 14.25% over the past 30 days and 35.33% over 90 days, while its 1 year total shareholder return sits at 22.08%. This points to building momentum...

Agilent Technologies (A) is back in focus after being highlighted as a key supplier to the expanding cannabis testing services market, along with a favorable analyst rank that points to improving earnings expectations and renewed investor interest. See our latest analysis for Agilent Technologies. The recent focus on Agilent Technologies as a key provider to cannabis testing services has coincided with a 19.31% 1 month share price return and a 35.39% 90 day share price return. The 1 year...

Stoke Therapeutics recently reported that its Phase III EMPEROR trial of zorevunersen in Dravet syndrome exceeded its 150-patient enrollment goal, reaching 162 patients with no discontinuations so far, and outlined plans to start a rolling FDA New Drug Application in the first quarter of 2027 and complete it by the third quarter of 2027. This smoother-than-expected enrollment, together with the clean retention profile, may strengthen confidence in the trial’s execution as the company...

Einride stock jumped 5.4% to $6.04 after its half year 2026 report, even as the headline story remains the strain on the balance sheet. The company is still generating losses, with basic earnings per share for the period at 17.85 SEK in the red and trailing twelve month losses near 78.77 SEK per share. That sits against a rich 16.1x price to sales multiple and a cash runway flagged as under one year. For investors, today’s move is less about a clean turnaround and more about how long the...

How IDACORP Stock Has Been Performing IDACORP (IDA) has drawn investor attention after recent trading left the stock about 4% lower over the past month, while total return over the past year remains about 14%. See our latest analysis for IDACORP. At a latest share price of US$140.76, IDACORP has seen recent momentum cool, with the 30-day share price return down 4.3%, even as the 1-year total shareholder return sits at about 14%. This points to a stock where long-term holders have still been...

Canadian Solar (NasdaqGS:CSIQ) is back in focus after a key legal overhang was removed. A long running U.S. patent infringement dispute with Maxeon Solar has now been resolved fully in Canadian Solar's favor. See our latest analysis for Canadian Solar. The legal win arrives as Canadian Solar's share price reacts sharply in the short term, with a 1 day share price return of 7.06% and a 30 day share price return of 3.82%, while the year to date share price return is down 37.90% and the 3 year...

Acadia Realty Trust (AKR) drew investor attention after extending a US$75 million loan to BTF Whitestone LLC to acquire and redevelop the Whitestone Shopping Center in Queens, a grocery anchored retail property. See our latest analysis for Acadia Realty Trust. Over the past year, Acadia Realty Trust has combined relatively muted recent share price moves with stronger longer term outcomes, with a 1 year total shareholder return of 14.18% and a 3 year total shareholder return of 66.73%. The...

In recent months, Crown Castle has been contending with a higher-for-longer interest rate backdrop while restructuring its balance sheet and reducing debt, even as a bankruptcy claim tied to tenant DISH Wireless introduces additional uncertainty. This combination of financing pressures and customer-related legal risk directly affects how secure Crown Castle’s cash flows may appear to investors and lenders. Next, we’ll examine how the interest rate pressure and DISH-related bankruptcy...

AbCellera Biologics (ABCL) drew fresh attention after reporting that its investigational antibody ABCL635 met primary efficacy endpoints in a Phase 2 trial for menopausal vasomotor symptoms, with statistically significant benefits versus placebo. See our latest analysis for AbCellera Biologics. Alongside the ABCL635 data, AbCellera Biologics has attracted fresh attention, with a 30 day share price return of 107.07% and a year to date share price return of 250.15%. The 1 year total shareholder...

With U.S. government debt now above $40b and Treasury yields at levels last seen before the global financial crisis, the cost of money is back in the spotlight. That shift can reshape which stocks benefit from higher rates and which feel pressure on valuations. This article looks at three stocks from a higher rate focused screener that appear particularly exposed to this move in markets and explains what that could mean for your portfolio. The stocks highlighted below are just a starting...

With the Fed minutes hinting that another rate hike is still on the table and inflation data hovering above the 2% target, short term cash and bond products linked to these decisions are back in the spotlight. This creates potential openings for investors watching short duration yields and money markets. This article first unpacks the backdrop, then walks through three stocks from our U.S. short duration and cash focused screener that appear positively exposed to this news. The stocks covered...

Exponent (EXPO) has caught investor attention after its recent share price move, with the stock up 3.6% over the past week and about 11.5% over the past month based on provided data. See our latest analysis for Exponent. Zooming out, Exponent’s recent 90 day share price return of 22.52% contrasts with a year to date share price move that is roughly flat. The 3 year and 5 year total shareholder returns show declines, which suggests momentum has picked up only in the shorter term as investors...

Green Plains earnings and production update Green Plains (GPRE) recently reported second quarter 2026 results that combined lower sales of US$446.22 million with a move to net income of US$67.15 million from a loss a year earlier. At the same time, the company released unaudited operating data that showed reduced ethanol, distillers grains, ultra high protein and renewable corn oil output compared with the prior year period, along with lower corn consumption. See our latest analysis for Green...

Dividend increase draws attention to Carlisle Companies stock Carlisle Companies (CSL) has drawn investor focus after its board approved a 14% increase in the regular quarterly dividend to $1.25 per share, payable on September 1, 2026. See our latest analysis for Carlisle Companies. Carlisle Companies’ dividend move comes after a period where the share price has shown positive momentum in recent months, with an 11.7% 1 month share price return and a 10.0% 3 month share price return, while the...